A r t i c l e s SB insertional mutagenesis is used for cancer gene discovery in animal models of both hematopoietic and solid tumors 1,2 . SB transposons can identify early cancer progression drivers, which cooperate to initiate tumors 3, 4 , and potential metastatic drivers 5, 6 , providing information about human cancer that is not easily obtained with current sequencing technology and limited patient samples.
A r t i c l e s SB insertional mutagenesis is used for cancer gene discovery in animal models of both hematopoietic and solid tumors 1,2 . SB transposons can identify early cancer progression drivers, which cooperate to initiate tumors 3, 4 , and potential metastatic drivers 5, 6 , providing information about human cancer that is not easily obtained with current sequencing technology and limited patient samples.
In mouse cancer models driven by insertional mutagenesis, transposon insertions in tumor cells are detected with PCR-based approaches to enrich for transposon-containing tumor DNA fragmented by enzymatic digestion or random shearing. These DNA fragments are then pooled, sequenced and mapped to the mouse genome. The method requires micrograms of input DNA, and PCR amplification of enzymatically fragmented DNA has a bias for recovery of insertions that occur within TA dinucleotides located <1 kb from the end of a DNA fragment. These limitations influence the detection of insertions and preclude the approach from application to small amounts of DNA isolated from laser-microdissected tumors or single cells.
We report the development of a transposon-sequencing method to identify SB transposon insertion sites from bulk tumor tissue and single tumor cells. Our approach relies on random shearing of genomic tumor DNA into discrete fragment sizes, which are then enriched for transposon sequences using liquid-capture hybridization with capture probes specific for the inverted repeats in the transposon termini. These capture probes are combined with blocking probes that are directed to the original transposon concatamer and prevent enrichment of unmobilized transposons from the donor site. Using Ion Torrent sequencing technology, SBCapSeq identifies insertions in a mouse model of AML in a semiquantitative manner whereby read depth can be used to identify clonally selected events. This is possible because captured fragments of discrete size are not subject to PCR bias or sequencing errors that occur in low-complexity amplicon-based libraries for NGS. We developed a bioinformatics pipeline to identify SB insertions in bulk tumor and single cells by mapping quality scores of sequence reads that contain both SB transposons and flanking genomic sequences that map uniquely to the mouse genome. Finally, we integrated data from whole-genome sequencing (WGS), SB capture hybridization and RNA-seq and found that SB insertions cause acute ML (AML) through overexpression of genes in the MAP kinase (MAPK) and JAK-STAT signaling pathways and identified cooperating mutagenic events in single tumor cells.
RESULTS
SB model of ML SB transposition in mice carrying an inducible SB transposase 7 and the Actb-Cre transgene 8 drives a rapidly fatal hematopoietic disease prominently affecting the spleen ( Fig. 1a and Supplementary Fig. 1a ).
Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with sBcapseq A r t i c l e s
Addition of an inducible Trp53-null (Trp53 +/− ) 9 or Trp53 point mutation (Trp53 R172H/+ ) 10 accelerated disease progression (P < 0.0001, Fig. 1a) . Trp53 R172H/+ mice died earlier than Trp53 +/− and wild-type mice and accumulated Trp53 protein in their tumor cells ( Supplementary  Fig. 1b-d) , results that are consistent with previous studies showing that missense mutations in Trp53 abrogate the tumor suppressor functions of Trp53 and promote malignant transformation [10] [11] [12] [13] [14] .
Mice from all three cohorts succumbed to an early, completely penetrant ML characterized by dense populations of undifferentiated cells in the red pulp (Fig. 1b) and subcapsular areas (Fig. 1c) of the spleen, with foci of tumor cells present in the liver (Supplementary Fig. 1e ). Approximately half of all tumors stained positive for the myeloid cell marker myeloperoxidase (MPO) in poorly differentiated regions ( Fig. 1d) and in the subcapsular area (Fig. 1e) . Many of the MPOpositive tumors were also positive for PAX5 staining under the capsule 15 ( Supplementary Fig. 1f ). PAX5 is found in human myeloid progenitors 16 . On the basis of these findings, we classified this disease as an undifferentiated ML, termed 'ML without maturation' in humans 17 .
Candidate cancer genes in mouse ML
We sequenced SB insertions sites from 168 mouse spleens and identified 27,889 nonredundant transposon insertion sites, which we used to statistically define 466 nonredundant candidate cancer genes (CCGs) by combining the data for all tumor cohorts analyzed together (Online Methods) and for cohorts based on Trp53 genotype analyzed separately (Supplementary Table 1 ). Most CCGs were identified across all cohorts independently, suggesting that their roles in ML are Trp53 independent.
Thirty-six CCGs are orthologs of human cancer genes found in the Cancer Gene Census 18 , a catalog of genes for which mutations have been causally implicated in cancer (P = 7.15 × 10 −8 , Bonferroni corrected). Another 110 CCGs, including Flt3 and Runx1, have human orthologs with mutations identified by exome or WGS 19 in at least one AML genome (P = 3.5 × 10 −7 , Bonferroni corrected). Notably, many CCGs overlapped with human AML CCGs that fall within the long-tail regions of nonsynonymous coding mutations identified by the Cancer Genome Atlas for AML 19 and with CCGs identified in two different mouse models of leukemia that also used SB mutagenesis 20, 21 (Supplementary Note). We conclude from these findings that SB captures the genes mutated by the diversity of mutational processes in human AML.
Previous studies suggest that most CCGs identified by SB mutagenesis function during tumor progression rather than initiation 3 . To identify ML CCGs that function in tumor initiation, we selected the SB insertion sites with the highest number of sequencing reads (Online Methods), reasoning that insertions that caused tumor initiation would be present in the largest number of tumor cells. We identified 35 putative 'trunk drivers' , genes involved in initiation and early progression of ML in vivo (Fig. 1f) . All statistically defined candidate cancer-associated genes identified in our analysis are drivers; our analysis does not define non-driver genes. AML patients who had mutations in one or more trunk drivers showed significantly P < 0.03 lower survival than patients lacking mutations in these genes (Supplementary Fig. 2a) . Notably, 80% of trunk drivers were involved in MAPK or JAK-STAT signaling.
Pathway enrichment analysis using all 466 CCGs identified MAPK and JAK-STAT signaling as significantly P < 0.001 enriched pathways (Supplementary Table 2) , similar to what is observed in human AML 22, 23 . Ninety-seven percent of our CCGs had a mutation in at least one gene involved in MAPK, JAK-STAT or Jun N-terminal kinase (JNK)-p38 MAPK pathways (Fig. 2a) . Notably, mutations in human homologs of the Sleeping Beauty-myeloid leukemia (SB-ML) CCGs that mapped to JAK-STAT or MAPK signaling are also associated with decreased survival in human AML (Supplementary Fig. 2c,d) . The most frequently mutated CCGs were Erg, Ets1 and Fli1, which encode ETS-related transcription factors and were collectively mutated in 80% of tumors. Insertions were primarily located in the 5′ end of each gene in the same transcriptional orientation, where they were predicted to drive expression of a truncated chimeric transcript containing the oncogenic ETS domain (Fig. 2b, top) . This hypothesis was subsequently confirmed by microarray analysis (Fig. 2b, bottom) . Rasgrf1
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A r t i c l e s
We also identified statistically significant (P < 0.05) co-occurrences of SB insertions in trunk drivers such as Ghr and Jak2 and mutually exclusive insertions in trunk drivers such as Erg and Ets1. These statistically defined relationships (Fig. 2c) indicate that cooperating oncogenic mutations drive leukemogenesis in this mouse model of human AML.
Capture hybridization enhances transposon insertion detection
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The SBCapSeq liquid-capture hybridization method uses capture probes specific for sequences located at the ends of the transposon to enrich for DNA fragments containing both transposon and mouse DNA before sequencing on the Ion Torrent Proton platform (Fig. 3a,b and Supplementary Fig. 3a) . A detailed protocol describing this method can be found at http://dx.doi.org/10.1038/protex.2016.053. To enable post-processing of sequence output from the Ion Torrent software suite, we designed a complementary SBCapSeq bioinformatics pipeline (Supplementary Fig. 3b ). After stringent read filtering and mapping, we retained an average of 4 × 10 5 reads per library for further analysis. The capture bias for right-or left-transposon inverted repeats was small ( Supplementary Fig. 4) , and most of the unmappable sequences were short reads that either mapped to the vector or did not meet the filtering criteria required for transposon or mouse genomic elements.
To evaluate the reproducibility and sensitivity of SBCapSeq, we constructed a DNA library from a single leukemic spleen and performed nine independent SBCapSeq reactions from the same sample. Sequence analysis demonstrated high reproducibility for detecting both reads and fragments, which are reads with identical start sites collapsed into a single unit (Fig. 3c) . A single sequencing run detected 50% of SB insertions at a read depth of ≥225, and 80% of the insertions identified by ≥5 fragments were identified in two runs. The fact that the number of single reads or fragments never reached saturation (Fig. 3c) suggests that they represent passenger insertions in which the transposon is maintained but does not confer a biological advantage. We also assessed the reproducibility of SBCapSeq to identify the same SB insertions using two independent sequencing runs for one tumor and found an overall high correlation between shared insertions and sequencing depth across experiments (Supplementary Fig. 5a ). When we specifically plotted insertions below the 95% precision cut-off, we found a negative correlation ( Supplementary Fig. 5b,c) . Using fragments instead of reads for the same two libraries showed an even higher correlation between experiments and a greater precision and recall, where the optimal F-measure and 95% precision are the same and fragments below the cut-off show no correlation ( Supplementary Fig. 5d-f) .
Comparison of SBCapSeq with other SB sequencing methods
Having shown that SBCapSeq identifies SB insertions with high reproducibility, we then compared insertion data generated by SBCapSeq for ten ML spleens previously analyzed by SB splinkerette PCR coupled with 454 sequencing (SB splink 454). SBCapSeq identified five times as many unique SB insertions as SB splink 454 (Fig. 4a) , and at least 50% of these insertions mapped to genes (Supplementary Table 3 ). SBCapSeq also identified genic insertions detected with high read counts that were not detected by SB splink 454. The narrow window of fragment sizes (225 ± 25 bp) isolated for capture and sequencing on the Ion Torrent platform (compared to the 200-to 400-bp range published by Friedel et al. 24 or the 100-to 1,000-bp range published by Koudijs et al. 25 ) ensures a more uniform amplification of all fragments during pre-and post-capture amplification steps and downstream sequencing representation. Thus, SBCapSeq can overcome a major limitation of restriction-enzyme-based splinkerette for detecting insertions (PCR bias for amplifying smaller fragments) 26 and enables detection of previously unknown clonal insertion events. We also compared the ability of each method to detect CCGs in MAPK, JAK-STAT and JNK-p38 pathways (Fig. 4b) . SBCapSeq identified seven insertions in CCGs that were missed by splink 454 in tumor C0117_SP, one of the tumors that we resampled (Fig. 4b) , and detected 18 CCGs in the 10 resampled tumors with at least two independent insertions in a single tumor (possibly a major clone and a minor clone), as defined by read counts for individual insertions. In contrast, splink 454 identified only two CCGs with multiple insertions in a single tumor. SBCapSeq detected multiple insertions per tumor in Erg (Fig. 4c ) and all insertions were in the correct position and orientation to activate Erg expression. SBCapSeq revealed a high degree of convergent tumor evolution that was not as apparent in the splink 454 data.
We next compared the SBCapSeq data from the ten ML samples to SB insertion data obtained using splink HiSeq 26 , a platform widely used for identifying SB insertions given the massive amount of obtainable sequencing reads 25 . We performed splinkerette PCR on randomly sheared genomic DNA using a modified version of the protocol published by Brett et al. 26 (Online Methods). Hierarchical clustering of insertions from splink 454, splink HiSeq and SBCapSeq shared by at least two platforms showed that in all but one sample, the data from SBCapSeq were closely related to the splink HiSeq output ( Supplementary Fig. 6a-j) . Insertions from SBCapSeq and splink HiSeq plotted by read depth showed high correlation (Pearson's correlation ≥0.8), indicating that SBCapSeq identifies the same insertion sites with the same representation as splink HiSeq but requires one-sixth of the DNA input for library preparation. Notably, 25% of the insertions detected with splink HiSeq were assigned to more than one sample, despite our use of staggered barcodes and double indexing to overcome errors caused by low library complexity 27, 28 . Notably, SBCapSeq yielded <0.01% cross-contamination of insertions in more than one sample, showing its higher sensitivity than Splink_HiSeq methods and potentially expanding the sequencing capability to single-cell sequencing.
Finally, we compared SBCapSeq to WGS as a benchmark of its quantitative nature. We sequenced a single leukemic spleen (sample D5) and normal tail from a sibling mouse (sample D6) using both methods. WGS identified unique SB insertions from D5 in 439 genes, including 28 CCGs identified previously (Fig. 5a) . The loci containing Col4a3/ Mff and Lmf1/Sox8 had the greatest number of reads for a single insertion (25 and 22, respectively), followed by four trunk drivers-Notch1 (21 reads), Ghr (19 reads), Erg (15 reads) and Ets1 (15 reads). Notch1 had a second unique insertion detected at 6 reads, suggesting coevolution in separate bulk tumor cells; both insertions were in the correct orientation to activate Notch1. WGS data from control sample D6 revealed only four insertions located on nondonor chromosomes represented by >2 reads, and no coevolving events were detected. SBCapSeq detected all but three of the insertions identified by WGS in D5 with ≥2 reads, at an average 947-fold increased read depth, and the read depth across the two platforms for the ML CCGs mutated in this tumor was highly correlated (Fig. 5b) . The output for SB insertion data is summarized in Figure 5c . Eighty-seven genes on nondonor chromosomes, including Erg, Ghr, Notch1 and Zmiz1, showed evidence, based on the detection of two or more insertions in independent TA dinucleotides, of coevolving SB insertion events. For several genes (Ankib1, Man2a1, Muc4, Plcxd3, Ptprt and Ryr3), a 'major' insertion was detected at ≥1,000 reads, in addition to one or more 'minor' insertions represented by ≥100 reads. This finding illustrates the high degree of intratumor heterogeneity in SB-induced tumors detectable by SBCapSeq. Considering shared insertions detected by SBCapSeq, WGS and/or splink HiSeq for this tumor, output from SBCapSeq and splink HiSeq were closely related ( Supplementary Fig. 6k,l) , with a Pearson correlation of 0.81, even with increased sequencing depth from SBCapSeq. Furthermore, SBCapSeq showed a higher correlation with WGS insertion data (Supplementary Fig. 6m ) than did splink HiSeq (Supplementary npg A r t i c l e s Fig. 6n) , suggesting that the fidelity of SBCapSeq for defining real SB insertions is also greater than that of splink HiSeq.
WGS confirms cytologically normal leukemic genome WGS showed that the D5 leukemia has a 'quiet' genome containing only 1,080 significant single-nucleotide variations (SNVs) and 160 significant insertions or deletions (indels), most of which map to introns and noncoding regions (Supplementary Fig. 7a and Supplementary Table 4) . Only five events occurred within exons, including a frameshift mutation in Olfr429; three nonsynonymous SNVs in Krt5, Tdrd6 and Tenm3; and one synonymous SNV in Lactb. None are ML CCGs or have known roles in leukemia, suggesting they are passenger mutations. In addition, no significant copy-number alterations (CNAs) were observed in the D5 leukemic genome across a 5-kb window, no translocation events were detected (Supplementary Fig. 7b ) and we could not find evidence for a significant mutational signature. WGS identified seven insertions containing a TACAG or TACTG sequence, which are the canonical SB mutagenic footprints 29 resulting from SB remobilization (Supplementary Table 4 ). Most of these footprints occurred on the donor chromosomes at a read depth on par with that of the SB insertions in trunk driver genes, indicating that we detected clonal footprints using WGS. Together, these data strongly suggest that SB mutagenesis is the predominant force driving tumor evolution.
Sequencing analysis of single-cell transposon insertions
We sorted live cells from the D5 leukemic spleen using the cell surface markers CD71 and Ter119, which we identified to be enriched on tumor cells (Supplementary Fig. 8a and Supplementary Note). 
A r t i c l e s
Each single-cell genome was screened for the presence or absence of a subset of SB insertions that are highly represented in the D5 bulk tumor, including insertions in trunk drivers Ets1 and Notch1 and in Ankib1, Phf2, Kdm4c and Zfp704 (Supplementary Fig. 8b ). We identified 26 distinct SB insertion patterns in 84 single cells, with 12 cells lacking insertions in any of these genes. This heterogeneity of SB insertion patterns was unexpected, given that insertions in these genes were represented by high read counts in bulk tumor DNA. Twenty-six cells representing the different insertion patterns were then sequenced by SBCapSeq to obtain the full complement of SB insertions in each cell. A total of 3,819 unique insertions were identified in the 26 single-cell genomes, with a median of 147 unique insertions per cell; 16.3% (622/3,819) of the insertions mapped to the donor chromosome, whereas 83.7% (3,197/3,819) mapped to nondonor chromosomes. This is a much lower frequency of donor chromosome insertions than the 50% observed in bulk tumor DNA and probably reflects the remobilization of transposons from the donor chromosome that we can observe in these enriched tumor cells. In total, 1,576 genes contained one or more SB insertion events among these 26 cells, and each cell had an average of 60 genic insertions. Only 27% of these genes were found to have insertions in the bulk tumor DNA by WGS or SBCapSeq. Forty-two of these genes were ML CCGs. Most insertions identified in single cells seem to represent unique insertion events and are probably passenger mutations. We also identified SB insertions in 58 ML CCGs in single cells not found in the bulk tumor by SBCapSeq or WGS, suggesting that these events were subclonal in this leukemia. Single-cell sequencing identified all but two of the insertional events detected by WGS with ≥2 reads and confirmed most events detected by SBCapSeq with ≥5 reads. This overlap suggests that we identified the major clonal subpopulations in this tumor by sequencing just 26 cells. The average number of insertional mutations in CCGs per cell was three, and no single cell had more than six mutated CCGs (Supplementary Table 5 ), suggesting that as few as three cooperating mutations are sufficient to drive clonal expansion. This observation is consistent with human studies that postulate that a typical tumor contains 2-8 driver gene mutations 30 .
We next performed hierarchical clustering, using the Hamming distance metric with Ward's linkage method, of SB insertions shared by three or more cells and assigned the 26 cells to two major clades (Fig. 6) . One population, composed of half of the sequenced cells, was anchored by an insertion in Erg, and all but one of these cells also had an insertion in Ghr. The Erg insertion may have occurred first, or the cell lacking a Ghr insertion may represent a false negative. Insertions in several other loci, including Kdm4c, Phf2 and Ankib1, were also 
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A r t i c l e s coincident with insertions in Erg and Ghr. None of these are CCGs, suggesting that they could be passenger mutations that were present in the cell before clonal expansion. The second major clade comprised two subpopulations of cells. A cluster of three Ter119 + cells at the right of the heat map had insertions in Ets1 and Notch1. Another Ter119 + cell (D5_SP_SC17) carried the Ets1 insertion but lacked the Notch1 insertion, whereas two Ter119 + cells (D5_SP_SC06 and D5_SP_SC09) had the Notch1 insertion but lacked the Ets1 insertion. D5_SP_SC17 may represent a false negative (a known error due to insufficient coverage during whole-genome amplification (WGA)) 31 , given that the rest of the cells in this clade contained a Notch1 insertion. Finally, one cell (D5_SP_SC95) had insertions in loci associated with both major clades, which suggests a failed single-cell sort. Six cells had few insertions in common with other cells and are likely to represent contaminating normal cells. When the analysis was expanded to include all insertions that mapped to ML CCGs and not just those shared in three or more cells, we found that most CCG insertions were unique to a single cell (Supplementary Fig. 8c ). This indicates that SB mutagenesis continues at a high level during clonal expansion, probably generating additional subclones as the tumor progresses and cells experience ongoing selective pressure. Notably, single-cell sequencing confirmed the cooperative relationship between Ets1 
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and Notch1 identified by population-based analysis and uncovered a possible cooperation between Erg and Ghr. Mapped SB insertions in single cells and D5 bulk tumor cells identified by SBCapSeq and SB insertions identified in the ML population by splink 454 for the trunk drivers Erg, Ghr, Ets1, Notch1 and Akt1 showed activating driver events predicted to upregulate gene expression from the minimal promoter from the transposon (Supplementary Fig. 9 ).
Gene-expression changes arise from SB insertions
To analyze the impact of clonally selected SB insertions on gene expression, we sequenced a poly(A)-enriched (mRNA-seq) library of total RNA isolated from the D5 leukemic spleen to identify chimeric spliced mRNA-seq reads containing transposon splice-donor or splice-acceptor sequences fused to adjacent known exons (SBfusions). We identified 1,331 SBfusion mRNA-seq reads from 682 RefSeq genes (Supplementary Table 6 ), and the top 2% of genes containing SBfusion transcripts were supported by ≥7 SBfusion reads and enriched for ML trunk drivers, including Erg, Notch1, Ghr and Ets1.
To confirm and extend the transcriptome analysis, we sequenced ribo-depleted, whole-transcriptome RNA-seq (wtRNA-seq) libraries from the D5 leukemic spleen, as well as two littermate control nonleukemic spleens in which SB was not mobilized, on the Ion Proton sequencing platform. Using the same modified SBCapSeq workflow, we identified 838 SBfusion RNA-seq reads from 48 genes and found increases in gene expression in leukemic cells for a number of ML trunk drivers, including Erg, Notch1, Ghr and Ets1 (Supplementary Table 6 ). CCGs with SB insertions in the sense orientation relative to the gene showed increased expression in the tumor over normal spleen; the same was true of insertions private to the D5 tumor predicted to activate gene expression (Supplementary Table 6 ). Insertions with high read counts led to greater changes in gene expression; however, insertions in CCGs and genes private to the D5 tumor oriented in the antisense direction rarely led to decreased gene expression in the tumor, indicating that they are passenger insertions and that this ML is largely an oncogene-driven disease.
Finally, we integrated the RNA-seq and insertion data for genes identified by single-cell sequencing to help distinguish between driver and passenger mutations. Figure 7 shows all of the genes identified in the two leukemic subpopulations, anchored by insertions in Erg and Ghr, or Ets1 and Notch 1. Figure 7a shows expressed SB-fusion transcripts for trunk drivers Erg and Ghr, in addition to Ankib1, Akap9, Fam65c, Cacnb4, Gak and Susd1, which might therefore also contribute to tumorigenesis. Upregulated SBfusion transcripts were also observed for three genes located on the donor chromosome, including Ncoa2, Vsig8 and Ppp1r7. Because these genes are on the donor chromosome, a role for these genes in leukemia induction is less certain. Figure 7b shows expressed fusion transcripts for trunk drivers Ets1 and Notch, which are both transcriptional targets of Runx1 (ref. 32 ), a major player in AML, and for Akt1. We also detected upregulated expression of Kif1a and Poglut1, which might contribute to leukemogenesis. These results provide additional strong evidence for the role of altered MAPK signaling in AML. Notably, six CCGs (Akt1, Erg, Ets1, Ghr, Ncoa2 and Notch1) represented in the bulk tumor at high read depth and confirmed as drivers by single-cell analysis were associated with a decrease in AML patient survival (P = 0.00021, Supplementary Fig. 2b ).
DISCUSSION
Although transposon mutagenesis can be used to identify cancercausing genes, it is challenging to identify trunk drivers that participate in tumor initiation. Trunk drivers are present in every tumor cell and may therefore be good drug targets. By sequencing transposon insertions from single tumor cells, SBCapSeq can identify both trunk drivers and potential cooperating cancer genes. We identified cooperating trunk drivers Erg and Ghr and Notch1 and Ets1 in two dominant tumor cell populations isolated from a SB model of human minimally differentiated, cytologically normal, acute ML. ERG is at the center of a regulatory program critical for hematopoietic stem cell maintenance 33 . In murine models, high Erg expression induces both T cell acute lymphoblastic leukemia (T-ALL) and AML 34 , and high ERG expression in both human AML 35 and early T cell precursor ALL is associated with poor clinical outcome. Growth hormone receptor (GHR) signaling has not been reported in AML, but growth hormone activates mitogenic signaling through JAK-STAT, MAPK-ERK and mTOR pathways 36 that are active in AML. NOTCH1 was found to be hyperexpressed in seven patients diagnosed with AMLs largely at stages M0 and M1 without morphological maturation 37 . Given our findings and the encouraging effects of γ-secretase inhibitors in preclinical models and now in clinical trials 38 for T-ALL patients with NOTCH1 hyperexpression, AML patients with increased NOTCH1 signaling may be an additional group worth studying in this context. Decreased ETS1 binding is required for normal erythroid maturation, and hyperactivated ETS1 expression may interfere with terminal erythroid differentiation 39 . Consistent with this, the subpopulation of leukemic cells containing Notch1 and Ets1 insertions in our data set expressed Ter119, a marker of late differentiation of erythroid cells. One unanticipated finding of our analysis was the large number of unique transposon insertions in every tumor cell. Recently, Sottoriva et al. 40 presented a 'Big Bang' model of human colorectal cancer (CRC) growth whereby tumors grow predominantly as a single expansion, producing many intermixed subclones not subject to stringent selection due to spatial constraints. Although our ML model is considerably more spatially unrestricted than CRC, we believe that it is still likely to follow the Big Bang model because of the high intratumor heterogeneity (ITH) with extensive subclone mixing. Until recently, it was thought that adult hematopoiesis is driven by the action of a small number of long-term multipotent hematopoietic stem cells; however, recent studies in mice have shown this is not the case 41, 42 . Lineage tracing in adult mice showed several-hundred-fold larger myeloid than lymphoid output, which could explain why the myeloid compartment is particularly susceptible to the effects of SB mutagenesis.
SBCapSeq is not limited to the study of ML. Using a conditional system 7 , SB transposition can be activated in virtually any hematopoietic cell using a lineage-specific Cre, with or without a sensitizing mutation, to model hematopoietic processes including disease. Furthermore, SBCapSeq can be extended to the study of solid tumors and cell-based screens. This capture-based approach can be adapted to any transposon-based system by modification of the capture and blocking oligos and therefore provides a tool to evaluate clonal dynamics and evolution in transposon model tumors. (in the mouse or transposon) of the read start. Sites with no discernable unique reads or orientations were discarded. Insertion sites in En2, Foxf2, or Serinc3 were discarded, as these contain sequences found in the transposon.
Mapping transposon insertion sites using splink 454. SB insertion reads were generated by 454 GS Titanium sequencing (Roche) of pooled splinkerette PCR reactions with nested, barcoded primers was performed 3, 47, 48 . Pre-and post-processing of 454 reads to assign sample DNA barcodes, filter out local hopping events from donor chromosomes, and map and orient the SB insertion sites across the entire nuclear genome of the mouse was performed. All SB insertions from donor chromosomes were filtered out before identification of common insertion sites using the Gaussian kernel convolution (GKC) 48, 49 and gCIS 26 methods.
Mapping transposon insertion sites using splink HiSeq. For selective SB insertion site sequencing by HiSeq (Illumina), we modified a published splinkerette PCR protocol 26 . gDNA (3 µg per sample) was acoustically sheared to 200 bp using Covaris S220 Focused-ultrasonicator and end repaired using Fast DNA End Repair Kit (Thermo Fisher Scientific). Adapters (linker+: 5′-GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA AGG GAC-3′ and linker-: 5′-Phos-GTC CCT TAA GCG GAG-C3spacer-3′) were annealed and ligated to repaired DNA. Purified repaired DNA was PCR amplified using linker (5′-GTA ATA CGA CTC ACT ATA GGG C-3′), IRR (5′-GGA TTA AAT GTC AGG AAT TGT GAA AA-3′), and IRL (5′-AAA TTT GTG GAG TAG TTG AAA AAC GA-3′) primers. Nested secondary PCR was performed using indexed SB-2ndR primer (5′-CAA GCA GAA GAC GGC ATA CGA GAT ( 
WGS.
For low coverage WGS from leukemic spleen, gDNA (1 µg) was used for library construction on the AB Library Builder System, including random fragmentation and ligation of barcoded Ion Xpress sequencing adapters. Adapter-ligated templates were purified by Agencourt AMPure beads and fragments with insert size of 200 bp were selected using Pippin prep (Sage Science), purified by Agencourt AMPure beads, amplified by eight cycles of aLM-PCR, and purified by Agencourt AMPure beads with elution in 50 µl of TE (1× Tris-EDTA, pH 8). Ion-WGS library fragments were run using an Agilent 2100 Bioanalyzer to estimate enrichment and quantified by Qubit Fluorometer and qRT-PCR to dilute libraries for template preparation and Ion Sphere Particle (ISP) loading using Ion OneTouch 2 System and sequencing on the Ion Proton platform with PI v2 semiconductor wafer chips per manufacturers recommended instructions. Raw sequencing read files were generated by Ion Torrent Suite. Data from four independent PI v2 chips were combined to achieve 31.1 GB representing 14.2× coverage of the mouse genome. Subsequent bioinformatic processing using BAM and/or FASTQ files was performed at Houston Methodist Research Institute using a custom built SBCaptureSeq analysis pipeline (see below). For high-coverage WGS from leukemic spleen and normal tail (from littermate of the same gender), gDNA (5 µg per sample) was used for paired-end library preparation (random fragmentation, ligation of sequencing adapters, and size selection), cluster generation (DNA binding to flow cell, primer extension, amplification, linearization, blocking and primer hybridization), and sequenced to 100× average genome coverage using 10 lanes per specimen on the Illumina HiSeq 2500 platform. Raw image files were processed using Illumina Consensus Assessment of Sequence and Variation (CASAVA 1.8.4) for base calling with default parameters and the sequences of each individual were generated as 100-bp paired-end reads. Library preparation and sequencing were performed by SeqWright. Bioinformatic processing using supplied FASTQ files was performed at Houston Methodist Research Institute using both a custom built mouse whole-genome analysis pipeline and a custom built SBCaptureSeq analysis pipeline.
Transcriptome sequencing. Total RNA was isolated from flash-frozen necropsy specimens using mirVana miRNA Isolation Kit (Ambion by Life Technologies, AM1560) from a shaved portion of leukemic spleen or the entire normal spleen (from two siblings that did not inherit the Actb-Cre transgene). For poly(A) RNA isolation (mRNA-seq), 5 µg total RNA isolated from D5 leukemic spleen was mixed with ERCC RNA Spike-In (Ambion by Life Technologies, 4456739) and used for poly(A) enrichment using Dynabeads mRNA DIRECT Micro Purification Kit (Ambion by Life Technologies, 61021). 200 ng poly(A)-enriched mRNA was used for whole-transcriptome library construction according to the Ion Total RNA-seq Kit v2 (Life Technologies, 4475936), protocol for non-barcoded libraries, Ion Sphere Particle (ISP) loading using Ion OneTouch 2 System and sequencing on the Ion Proton platform with PIv2 semiconductor wafer chips per the manufacturer's instructions. For whole-transcriptome RNA-seq (wtRNA-seq), total RNA (5 µg per sample) plus ERCC RNA Spike-In (Ambion by Life Technologies, 4456739) was used for selective ribosomal RNA (rRNA) depletion using the RiboMinus Eukaryote System v2 (Ambion by Life Technologies, A15026). rRNA-depleted total RNA (500 ng per sample) was used for whole-transcriptome library construction according to the Ion Total RNA-seq Kit for the AB Library Builder System (Life Technologies, 4482416) protocol for barcoded libraries, Ion Sphere Particle (ISP) loading using Ion OneTouch 2 System and sequencing on the Ion Proton platform with PI v3 semiconductor wafer chips per manufacturers recommended instructions. Each RNA-seq library was sequenced individually on a PI v2 chip to achieve >4 GB (~70 million reads) per specimen. The Life Technologies Torrent Suite software was used to perform checking of the raw sequence data before the generation of sequencing read files in FASTQ format. Minimally processed mRNA-seq and wtRNA-seq reads were processed using Bowtie 50 and Tophat 51 algorithms to align reads to a custom version of the mouse mm9 genome, which included the pT2/Onc transposon sequence as an additional chromosome (denoted mm9+pT2/Onc).
Microarray gene-expression analysis. Gene-expression profiling of SB-ML mouse spleens was performed using Affymetrix microarrays. RNA was extracted using a NORGEN Biotek Animal Tissue RNA Purification kit (25700) per the manufacturer's instructions. RNA was then labeled using an Affymetrix 3′ IVT Express kit (901229) using 100 ng total RNA for each sample per the manufacturer's instructions. After labeling, samples were hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays, and scanned at the University of Otago Genomics and Bioinformatics Facility. Raw data were processed in R (version 2.15) 52 using the 'rma' function of the 'affy' package 53 (quantile normalization, no background correction). The 'affyQCReport' package (http://rpackages.ianhowson.com/bioc/affyQCReport/) or R 52 was used to perform quality assessment of the microarray data.
Identification of common insertion sites. Identification of statistically significant common insertion sites (CISs), cooperating loci, and SB insertion abundance profiles was performed using a BED-formatted file containing the genomic locations of the filtered list of SB insertion sites from the SB-ML genomes.
Trunk driver analysis. The BED file containing all SB insertions from the 168 ML spleens sequenced by splink 454 was filtered to consider only insertions represented by five or more reads in three or more tumors. When genes from a ML genome were found to contain ≥1 SB insertion in the same RefSeq gene, only the SB insertion with the highest sequence read count was used for gCIS calculations. gCIS statistical analysis was then performed to identify the genes significantly enriched for insertions at high read counts with a corrected P < 0.05. 35 genes met these criteria and were termed trunk driver genes on the basis of the inferred high clonality across the tumor population. npg Pathway analysis. Three independent databases, IPA (Ingenuity Pathway Analysis), DAVID (Database for Annotation, Visualization and Integrated Discovery) and GATHER (Gene Annotation Tool to Help Explain Relationships) were used to interrogate all ML CCGs for the enrichment of specific signaling pathways and processes.
Variant calling in WGS. Genomic variants (SNVs, indels and CNAs) were identified in the WGS data using an analysis pipeline centered on the VarScan2 (version 2.3.6) 54 . This involved alignment to a custom genomic reference containing the mm9 genome and the T2/Onc2 transposon sequence (mm9+pT2/ Onc) using BWA followed by creation of mpileup files using samtools (version 0.1.19-44428cd) 55 . These files were then used as the input to VarScan2 for calling SNVs and indels followed by ANNOVAR (accessed 23 August 2013) 56 software to assign potential functional relevance. The indel data were used to identify putative 'footprints' of previous SB transposon presence, by filtering for sequence motifs known to be indicative of transposon excision. CNV regions were identified using VarScan2 and further analyzed in R 52 using the DNAcopy package (version 1.36.0) 57 to find areas of gain and loss.
Detecting SB-fusion events in RNA-seq data. Sequencing reads from poly(A) and ribo-depleted libraries were aligned to the Lun-splice donor, En2 splice acceptor, and non-En2 splice acceptor regions of the T2/Onc2 sequence in Bowtie2 (ref. 50) using the '-very-sensitive-local' flag. The CIGAR string associated with mapped reads was used to clip away the transposon portion, and resulting sequences <20 bp were discarded. Remaining sequences were then aligned to the mm9+pT2/Onc2 reference using Bowtie 2 with the '-verysensitive' flag enabled. Reads that failed to map, mapped with a MAPQ less than 30, or mapped to T2/Onc2 were discarded. The coordinates of the mousegenome fusion, the associated region in the transposon, and the orientation of the read relative to the genome were recorded in BED format.
Defining novel SB-fusion transcripts. Using the SB insertion and fusion information, along with reference transcript annotations (downloaded from UCSC in genePred format and converted to GTF format), we identified three types of novel transcripts that contained SB insertion and fusion information. To do this, we first identified SB insertions as being activating or inactivating: activating when the insertion orientation (defined with respect to the chromosome) is sense with the gene, and inactivating when the insertion orientation is antisense with the gene. The first type of novel transcript was defined as having a splice acceptor fusion in the exon upstream of an activating insertion (SB_5p). The second was defined as containing a splice donor in the exon downstream of an activating insertion (SB_3p). The third type was defined as having an En2 splice acceptor fusion in the exon upstream of an inactivating insertion (SB_5palt). Insertions within 15 kb upstream of a gene-coding region were associated with the transcripts from the downstream gene. Code availability and software. Source code and scripts used are available in Supplementary Code. Unless otherwise noted, the aforementioned analysis pipelines, report generation, and figure visualization performed using bash, R, and Python scripts. The circular genomic plots in Supplementary  Figure 5a ,b were generated using the R package circlize 60 . Hierarchical clustering was performed in Python 2.7.10 with the scipy 0.13.0b1 toolbox using the Hamming distance metric with Ward's linkage method. The R packages ggplot2 (ref. 61) and Gviz 62 were used to generate the graphics in Figure 7 .
